UY36315A - COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6. - Google Patents
COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6.Info
- Publication number
- UY36315A UY36315A UY0001036315A UY36315A UY36315A UY 36315 A UY36315 A UY 36315A UY 0001036315 A UY0001036315 A UY 0001036315A UY 36315 A UY36315 A UY 36315A UY 36315 A UY36315 A UY 36315A
- Authority
- UY
- Uruguay
- Prior art keywords
- avß6
- antigonist
- integrine
- compounds
- new
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1417011.2A GB201417011D0 (en) | 2014-09-26 | 2014-09-26 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY36315A true UY36315A (es) | 2016-04-29 |
Family
ID=51901167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001036315A UY36315A (es) | 2014-09-26 | 2015-09-22 | COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10000489B2 (enExample) |
| EP (1) | EP3197893B1 (enExample) |
| JP (1) | JP6665169B2 (enExample) |
| KR (1) | KR20170063590A (enExample) |
| CN (1) | CN107074849A (enExample) |
| AR (1) | AR101995A1 (enExample) |
| AU (1) | AU2015320859A1 (enExample) |
| BR (1) | BR112017006253A2 (enExample) |
| CA (1) | CA2962326A1 (enExample) |
| ES (1) | ES2704525T3 (enExample) |
| GB (1) | GB201417011D0 (enExample) |
| RU (1) | RU2017114346A (enExample) |
| TW (1) | TW201629057A (enExample) |
| UY (1) | UY36315A (enExample) |
| WO (1) | WO2016046226A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201604681D0 (en) * | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| EP3538528B1 (en) | 2016-11-08 | 2020-12-23 | Bristol-Myers Squibb Company | Pyrrole amides as alpha v integrin inhibitors |
| TW201819378A (zh) | 2016-11-08 | 2018-06-01 | 美商必治妥美雅史谷比公司 | 作為αｖ整合素抑制劑之含環丁烷及氮雜環丁烷之單及螺環化合物 |
| PL3538525T3 (pl) | 2016-11-08 | 2022-09-12 | Bristol-Myers Squibb Company | 3-podstawione kwasy propionowe jako inhibitory integryny alfa v |
| US10745384B2 (en) | 2016-11-08 | 2020-08-18 | Bristol-Myers Squibb Company | Indazole derivatives as αv integrin antagonists |
| EA201991121A1 (ru) | 2016-11-08 | 2019-11-29 | АЗОЛАМИДЫ И АЗОЛАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕГРИНОВ αV | |
| EP3558303A4 (en) | 2016-12-23 | 2020-07-29 | Pliant Therapeutics, Inc. | AMINO ACID COMPOUNDS AND PROCESSES FOR USE |
| CA3054792A1 (en) | 2017-02-28 | 2018-09-07 | Morphic Therapeutic, Inc. | Inhibitors of .alpha.v.beta.6 integrin |
| MX394210B (es) | 2017-02-28 | 2025-03-04 | Morphic Therapeutic Inc | INHIBIDORES DE INTEGRINA AVß6. |
| CN107823208A (zh) * | 2017-10-25 | 2018-03-23 | 南京多宝生物科技有限公司 | 吗啉类化合物在制备治疗和预防肾纤维化药物中的应用 |
| KR102700471B1 (ko) | 2017-11-07 | 2024-08-28 | 브리스톨-마이어스 스큅 컴퍼니 | 알파 v 인테그린 억제제로서의 피롤로피라진 유도체 |
| CN108208177A (zh) * | 2017-11-28 | 2018-06-29 | 上海交通大学医学院附属新华医院 | 含丁酸类化合物的组合物及其应用 |
| FI3844162T3 (fi) | 2018-08-29 | 2025-03-27 | Morphic Therapeutic Inc | Alfa v beeta6 -integriinin estäjiä |
| JP7540998B2 (ja) | 2018-08-29 | 2024-08-27 | モーフィック セラピューティック，インコーポレイテッド | αｖβ６インテグリンの阻害 |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| WO2020074937A1 (en) * | 2018-10-09 | 2020-04-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of alpha-v-integrin (cd51) inhibitors for the treatment of cardiac fibrosis |
| CA3119807A1 (en) * | 2018-12-04 | 2020-06-11 | Sumitomo Dainippon Pharma Oncology, Inc. | Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| EP4525866A1 (en) * | 2022-05-18 | 2025-03-26 | Pliant Therapeutics, Inc. | Stabilization of integrin inhibitors |
| EP4605008A1 (en) | 2022-12-14 | 2025-08-27 | Alnylam Pharmaceuticals, Inc. | Alpha-v beta-6 integrin ligands for extrahepatic delivery |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999030709A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| NZ504893A (en) | 1997-12-17 | 2002-10-25 | Merck & Co Inc | 5, 6, 7, 8-Tetrahydro-[1,8]-naphthyridin-2-yl derivatives useful as integrin receptor antagonists |
| CA2373937A1 (en) | 1999-06-02 | 2000-12-07 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| AU748949B2 (en) | 1999-06-23 | 2002-06-13 | Merck & Co., Inc. | Integrin receptor antagonists |
| CA2386030A1 (en) | 1999-10-04 | 2001-04-12 | Merck & Co., Inc. | Integrin receptor antagonists |
| WO2001034602A2 (en) | 1999-11-08 | 2001-05-17 | Merck & Co., Inc. | Process and intermediates for the preparation of imidazolidinone alpha v integrin antagonists |
| JP2004511434A (ja) | 2000-06-15 | 2004-04-15 | ファルマシア・コーポレーション | インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸 |
| DE60126496T2 (de) | 2000-07-26 | 2007-11-15 | Merck & Co., Inc. | Alpha v integrin-rezeptor-antagonisten |
| WO2002022616A2 (en) | 2000-09-14 | 2002-03-21 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| EP1349548A4 (en) | 2001-01-03 | 2004-06-02 | Merck & Co Inc | METHOD AND COMPOSITIONS FOR TREATING PERIODONTOSIS |
| DE10112771A1 (de) | 2001-03-16 | 2002-09-26 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
| US20040224986A1 (en) * | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| CA2507699A1 (en) | 2002-12-20 | 2004-07-15 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists |
| US6932865B2 (en) | 2003-04-11 | 2005-08-23 | Lockheed Martin Corporation | System and method of making single-crystal structures through free-form fabrication techniques |
| RS53151B (sr) | 2007-03-23 | 2014-06-30 | Amgen Inc. | 3-supstituisani derivati hinolina ili hinoksalina i njihova upotreba kao inhibitora fosfatidilinozitol 3-kinaze (pi3k) |
| EP2211615A4 (en) | 2007-10-22 | 2010-10-13 | Glaxosmithkline Llc | PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS |
| WO2011111880A1 (ko) | 2010-03-08 | 2011-09-15 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
| GB201305668D0 (en) * | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| WO2015048819A1 (en) | 2013-09-30 | 2015-04-02 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| JP2018510139A (ja) | 2015-02-19 | 2018-04-12 | サイフルーア ライフ サイエンシズ インコーポレイテッド | フッ化テトラヒドロナフチリジニルノナン酸誘導体およびその使用法 |
| AU2016228852A1 (en) | 2015-03-10 | 2017-10-19 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| GB201604589D0 (en) | 2016-03-18 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical compound |
| GB201604681D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
-
2014
- 2014-09-26 GB GBGB1417011.2A patent/GB201417011D0/en not_active Ceased
-
2015
- 2015-09-22 ES ES15767476T patent/ES2704525T3/es active Active
- 2015-09-22 CA CA2962326A patent/CA2962326A1/en active Pending
- 2015-09-22 US US15/514,407 patent/US10000489B2/en not_active Expired - Fee Related
- 2015-09-22 JP JP2017516365A patent/JP6665169B2/ja not_active Expired - Fee Related
- 2015-09-22 AR ARP150103048A patent/AR101995A1/es unknown
- 2015-09-22 AU AU2015320859A patent/AU2015320859A1/en not_active Abandoned
- 2015-09-22 EP EP15767476.3A patent/EP3197893B1/en active Active
- 2015-09-22 KR KR1020177007734A patent/KR20170063590A/ko not_active Withdrawn
- 2015-09-22 TW TW104131367A patent/TW201629057A/zh unknown
- 2015-09-22 RU RU2017114346A patent/RU2017114346A/ru unknown
- 2015-09-22 CN CN201580051539.2A patent/CN107074849A/zh active Pending
- 2015-09-22 UY UY0001036315A patent/UY36315A/es not_active Application Discontinuation
- 2015-09-22 WO PCT/EP2015/071777 patent/WO2016046226A1/en not_active Ceased
- 2015-09-22 BR BR112017006253A patent/BR112017006253A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP3197893A1 (en) | 2017-08-02 |
| WO2016046226A1 (en) | 2016-03-31 |
| KR20170063590A (ko) | 2017-06-08 |
| EP3197893B1 (en) | 2018-10-24 |
| US20170298063A1 (en) | 2017-10-19 |
| JP2017528503A (ja) | 2017-09-28 |
| RU2017114346A (ru) | 2018-11-02 |
| TW201629057A (zh) | 2016-08-16 |
| CA2962326A1 (en) | 2016-03-31 |
| US10000489B2 (en) | 2018-06-19 |
| CN107074849A (zh) | 2017-08-18 |
| ES2704525T3 (es) | 2019-03-18 |
| GB201417011D0 (en) | 2014-11-12 |
| JP6665169B2 (ja) | 2020-03-13 |
| AR101995A1 (es) | 2017-01-25 |
| BR112017006253A2 (pt) | 2017-12-12 |
| AU2015320859A1 (en) | 2017-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY36315A (es) | COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6. | |
| ECSP17010156A (es) | Compuestos aminopirimidinilo como inhibidores jak | |
| PL3519420T3 (pl) | Cykliczne związki dinukleotydowe | |
| MX2018006148A (es) | Inhibidores de cxcr2. | |
| CL2016001458A1 (es) | Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo. | |
| UY36314A (es) | NUEVOS COMPUESTOS ANTAGONISTAS DE INTEGRINA avß6. | |
| HUE049921T2 (hu) | Gyomirtó propinil-fenil-vegyületek | |
| HUE048341T2 (hu) | Új diszubsztituált 1,2,4-triazin-vegyület | |
| DOP2017000178A (es) | Inhibidores selectivos de bace1 | |
| BR112017005883A2 (pt) | compostos herbicidas | |
| AR105967A1 (es) | Sales de un inhibidor de pim quinasa | |
| CL2016001349A1 (es) | Uso de derivados de bencimidazol-prolina | |
| DK3197890T3 (da) | Disubstituerede diaryloxybenzoheterodiazolforbindelser | |
| BR112017023150A2 (pt) | compostos herbicidas. | |
| EA201790982A1 (ru) | Синтез копанлисиба и его дигидрохлорида | |
| BR112016029117A2 (pt) | compostos herbicidas | |
| MX2016015118A (es) | Estimacion del volumen de sangre absoluto usando hemodilucion. | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
| EA201691999A1 (ru) | Новые сульфониламинобензамидные соединения | |
| BR112016027455A2 (pt) | moduladores ppar | |
| MX2018007415A (es) | Metodos para preparar 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-ami na sustituida. | |
| DK3374357T3 (da) | Disubstituerede diaryloxybenzoheterodiazol-forbindelser | |
| MX2017006110A (es) | Carboxamidas de quinolina para usarse en el tratamiento de leucemia. | |
| BR112017002139A2 (pt) | ?método para preparar um composto? | |
| CL2016003154A1 (es) | Composiciones herbicidas sólidas que contienen un fitoprotector |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20220705 |